Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) has entered a clinical trial collaboration with Eli Lilly and Co. to evaluate an experimental breast cancer treatment alongside two Lilly drugs, …
Prelude Partners With Lilly to Test Breast Cancer Drug Combinations Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) has dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002, an experimental antibody-drug conjugate targeting ovarian and …
ArriVent Advances Cancer Drug Pipeline With First U.S. Trial Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis treatment ICOTYDE maintained clear or almost clear skin through two …
Johnson & Johnson Reports Sustained Psoriasis Drug Response Read More
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported additional clinical evidence that its experimental hypertension drug lorundrostat can lower blood pressure in patients whose condition remains uncontrolled despite multiple …
Mineralys Drug Lowers Blood Pressure but Misses Sleep Apnea Goal Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) said its experimental lung cancer drug firmonertinib failed to significantly improve progression-free survival compared with chemotherapy in a pivotal Phase 3 …
ArriVent’s Lung Cancer Drug Fails Key Phase 3 Trial Endpoint Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that its liver disease drug Rezdiffra improved measures of liver damage across patients carrying common genetic risk variants for metabolic dysfunction-associated …
Madrigal Study Finds Rezdiffra Benefits Across Genetic Risks Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained skin clearance through 112 weeks in a Phase 3 clinical study, providing …
Johnson & Johnson Psoriasis Drug Sustains Clearance at Two Years Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that adolescents with generalized myasthenia gravis maintained improvements in daily function and muscle strength through two years of IMAAVY treatment, …
J&J’s IMAAVY Maintains Gains in Two-Year Adolescent Study Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present Phase 3 data this month examining whether its experimental hypertension drug lorundrostat reduced both blood pressure and albuminuria in patients …
Mineralys Extends Lorundrostat Focus to Kidney Disease Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) remains on track to seek U.S. clearance in the fourth quarter to begin clinical testing of CNTY-813, its experimental type 1 diabetes …
Century Advances Diabetes Cell Therapy Toward FDA Filing Read More